从N-aryl-chitosan衍生物中开发一个阴离子生物纳米复合体,用于控制药物释放的药物
Samir E Esquivel1, Matías Rebolledo1, Elizabeth R Gilles2
1Biobased and Bioinspired Biomaterials Research Group and Laboratory of Functional Polymers and Environment, Departamento de Polímeros, Facultad de Ciencias Químicas, Universidad de Concepción, Casilla 160-C, Concepción, Chile.
Carbohydrate polymers
|March 14, 2026
概括
阿里尔修饰的奇托桑生物纳米复合物提供了改善的药物输送. 这些新型系统显示出良好的生物相容性和可控释放的迪克洛菲纳克,素和四环素,以提高治疗效果.
科学领域:
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
- 生物医学工程 生物医学工程
背景情况:
- 传统的药物输送系统面临着诸如溶解性差和不受控制的释放等挑战.
- 生物纳米复合物为持续活性成分释放提供了一个有希望的替代方案.
研究的目的:
- 开发和描述使用基改性基托衍生物的阴性生物纳米复合物.
- 为了评估二甲,素和四环素的受控释放.
- 评估开发的生物纳米复合体的生物相容性和稳定性.
主要方法:
- 合成和表征酸盐衍生物的酸 (OHCh) 和酸三甲基 (TMACh).
- 生物纳米复合物的制备和形态分析 (球形颗粒,~200nm).
- 体稳定性测试 (pH,离子强度,温度,时间) 和细胞毒性测试 (HCT116细胞).
- 药物负载研究和体外释放动力学 (迪克洛芬雅克,光素,四环素).
主要成果:
- 通过1H NMR证实了高的替代和四度化程度.
- 生物纳米复合体表现出环境敏感性和大量的胀 (约787%).
- 环素的封装度最高 (69%),狄克洛菲纳克的释放速度最快 (5小时内62%).
- 药物释放遵循非Fickian (Korsmeyer-Peppas) 或Higuchi扩散模型.
结论:
- 基改性奇多生物纳米复合物表现出良好的生物相容性和受控释放性质.
- 这些生物纳米复合体是各种活性药物成分的有效载体.
- 开发的系统显示了先进的药物输送应用的巨大潜力.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
296
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
296
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
01:11Oral Drug Delivery Systems: Delayed-Release Systems
96
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
96
01:24Modified-Release Drug Delivery Systems: Site-Targeted
71
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
71
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
73
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
73
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
119
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
119